Crenigacestat is primarily investigated for its potential in cancer treatment, particularly targeting Notch signaling pathways. It is being studied in clinical trials for various cancers, including solid tumors and hematologic malignancies. The compound works by inhibiting gamma-secretase, an enzyme involved in the activation of Notch receptors, which play a key role in cancer cell proliferation and survival. Its application is focused on disrupting tumor growth and improving therapeutic outcomes, especially in cases where Notch signaling is dysregulated. Research continues to explore its efficacy and safety in combination with other anticancer therapies.